Showing results (61-70 of 83) with videos related to

Sort By:
Pageof 9
Cancer|October 18, 2018
Return to work after breast cancer diagnosis: An observational prospective study in BrazilLuciana C G Landeiro, Debora M Gagliato, Angelo B Fêde, et al.
Clinical Drug Investigation|August 18, 2023
Expanded Access Study of Palbociclib Plus Letrozole for Postmenopausal Women with HR+/HER2- Advanced Breast Cancer in Latin America for Whom Letrozole Therapy is Deemed AppropriateLuis Fein, Nicolas Lazaretti, Yamil López Chuken, et al.
Environmental Science and Pollution Research International|January 7, 2015
Leydig cell number and sperm production decrease induced by chronic ametryn exposure: a negative impact on animal reproductive healthT A Dantas, G Cancian, D N R Neodini, et al.
Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Medicas E Biologicas|March 12, 2015
Metronomic chemotherapy in the neoadjuvant setting: results of two parallel feasibility trials (TraQme and TAME) in patients with HER2+ and HER2- locally advanced breast cancerV Petry, D M Gagliato, A I C Leal, et al.
Experimental and Toxicologic Pathology : Official Journal of the Gesellschaft Fur Toxikologische Pathologie|August 28, 2015
Toxicological evaluation of ametryn effects in Wistar ratsTamires Santos, Graziela Cancian, Daniella N R Neodini, et al.
Breast Care (Basel, Switzerland)|November 19, 2014
Cardiac safety of (neo)adjuvant trastuzumab in the community setting: a single-center experienceLeonardo Gomes da Fonseca, Debora de Melo Gagliato, Tiago K Takahashi, et al.
Journal of Global Oncology|November 27, 2019
Cross-Cultural Validity Study of a Medical Education Leadership Competencies Instrument in Latin American Physicians: A Multinational StudyMax S Mano, Rafaela Gomes, Gustavo Werutsky, et al.
NPJ Breast Cancer|September 18, 2022
Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINESibylle Loibl, Chiun-Sheng Huang, Max S Mano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 2, 2023
Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast CancerCarsten Denkert, Chiara Lambertini, Peter A Fasching, et al.
The Lancet. Oncology|June 21, 2015
Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trialSara A Hurvitz, Fabrice Andre, Zefei Jiang, et al.
Pageof 9